Page last updated: 2024-12-05

sodium tetradecyl sulfate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID23665770
CHEMBL ID541505
SCHEMBL ID28992
MeSH IDM0020118

Synonyms (49)

Synonym
sodium tetradecyl sulfate ,
sodium myristyl sulfate
1191-50-0
tetradecyl sulfate sodium salt, 95%
1-tetradecanol, hydrogen sulfate, sodium salt
sulfuric acid, monotetradecyl ester, sodium salt
natrii tetradecyclis sulfas [inn-latin]
tetradecyl sulfate de sodium [inn-french]
tesapon k 14
nsc 139032
niaproof 4
natri tetradecylsulfas
tetradecilsulfato sodico [inn-spanish]
einecs 214-737-2
sulfuric acid, myristyl ester, sodium salt
tetradecyl sulfate sodium salt
CHEMBL541505
1-tetradecanol, 1-(hydrogen sulfate), sodium salt (1:1)
unii-2x50fw96ys
2x50fw96ys ,
natrii tetradecyclis sulfas
NCGC00254331-01
dtxcid208726
tox21_300376
dtxsid4042416 ,
cas-1191-50-0
FT-0633445
AKOS015912587
SCHEMBL28992
1-tetradecanol, hydrogen sulphate sodium salt
sodium myristyl sulphate
sodium n-tetradecyl sulfate
1-tetradecanol, 1-(hydrogen sulphate), sodium salt (1:1)
sodium n-tetradecyl sulphate
sodium myristyl sulfate [inci]
J-004075
sodium 1-tetradecyl sulfate ,
mfcd00007468
UPUIQOIQVMNQAP-UHFFFAOYSA-M
AS-69862
sodium;tetradecyl sulfate
Q27255739
CS-0356213
tetradecyl sulfate (sodium)
sodiumtetradecylsulfate
EN300-6766365
?sodium tetradecyl sulfate
HY-W195048
E85523

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The method of preparation and the procedure itself may be considered safe and effective in the treatment of esophagogastric varices."( Eleven-year survey of safety and efficacy of endoscopic injection sclerotherapy using 2% sodium tetradecyl sulfate and contrast medium.
Horiuchi, Y; Iwase, H; Oohashi, M; Shimada, M; Suga, S; Yamada, H, 1996
)
0.29
" According to our actual experience and knowledge, the safe amount of foam should not exceed the 3-ml limit, but further advancements could come from standardization of the foam preparation technique."( Sclerosing foam in the treatment of varicose veins and telangiectases: history and analysis of safety and complications.
Cavezzi, A; Frullini, A, 2002
)
0.31
"In most patients, ultrasound-guided foam sclerotherapy is a safe treatment for recurrent varicose veins, with an excellent immediate result."( Effectiveness and safety of ultrasound-guided foam sclerotherapy for recurrent varicose veins: immediate results.
Azzam, M; Bountouroglou, DG; Daskalopoulos, M; Geroulakos, G; Kakkos, SK; Kalodiki, E, 2006
)
0.33
" In addition, major adverse effects were rare."( Efficacy and safety of endovenous foam sclerotherapy: meta-analysis for treatment of venous disorders.
Norris, A; Rathbun, S; Stoner, J, 2012
)
0.38
"EFS is a safe and effective therapy for the treatment of venous disorders."( Efficacy and safety of endovenous foam sclerotherapy: meta-analysis for treatment of venous disorders.
Norris, A; Rathbun, S; Stoner, J, 2012
)
0.38
"A telephone-based questionnaire was used for patient self-assessment of overall improvement, satisfaction, and adverse events."( Foam sclerotherapy for reticular veins of the chest: a retrospective review of efficacy and safety.
Cruz-Inigo, AE; Friedmann, DP; Goldman, MP, 2015
)
0.42
"6 for satisfaction with results (0 = not satisfied at all, 1 = mildly satisfied, and 2 = very satisfied), with minor treatment-related adverse events."( Foam sclerotherapy for reticular veins of the chest: a retrospective review of efficacy and safety.
Cruz-Inigo, AE; Friedmann, DP; Goldman, MP, 2015
)
0.42
"BRTO using STS liquid can be a safe and useful treatment option in patients with gastric varices."( Efficacy and Safety of Balloon-Occluded Retrograde Transvenous Obliteration with Sodium Tetradecyl Sulfate Liquid Sclerotherapy.
Chang, IS; Cheon, YK; Choe, WH; Kim, JH; Kwon, SY; Lee, TY; Park, SW; Shim, CS,
)
0.13
"Our experience suggests STS foam is a safe and effective agent for patients with large shunt undergoing BRTO."( Safety and Efficacy of Sodium Tetradecyl Sulfate and Lipiodol Foam in Balloon-Occluded Retrograde Transvenous Obliteration (BRTO) for Large Porto-Systemic Shunts.
Deogaonkar, G; Mukund, A; Rajesh, S; Sarin, SK; Shasthry, SM, 2017
)
0.46
"Combined Nd:YAG laser therapy and sclerotherapy allows treatment of both superficial and deep components of VMs in a safe and efficient manner."( Combined Nd:YAG laser and bleomycin sclerotherapy under the same anesthesia for cervicofacial venous malformations: A safe and effective treatment option.
Burrows, PE; Chun, RH; Ellinas, H; Gregory, S; Stadler, M, 2018
)
0.48
"The authors performed a disproportionality analysis using the proportional reporting ratio (PRR) method to compare pharmacovigilance signals between each sclerosing agent among 6 adverse event syndromes of interest: hypersensitivity reactions, arterial thromboembolic disorders, venous thromboembolic disorders, cardiac arrhythmias, visual/neurological disturbances, and skin ulcerations."( Safety Profile of Sclerosing Agents: An Analysis From the World Health Organization Pharmacovigilance Database VigiBase.
Blaise, S; Cracowski, JL; Khouri, C; Roselli, A; Roustit, M, 2019
)
0.51
" No patients experienced adverse hemodynamic consequences or venous thromboembolism."( Safety and efficacy of foam sclerotherapy for treatment of low-flow vascular malformations in children.
Markovic, JN; Nag, U; Shortell, CK, 2020
)
0.56
" Technical success rate, primary occlusion rate, adverse effects, and recanalization rates were evaluated."( Mechanochemical Endovenous Ablation of Varicose Veins in Pediatric Patients with Klippel-Trénaunay Syndrome: Feasibility, Safety, and Initial Results.
Cabezas, M; Garriga, M; Lambert, G; Oliva, A; Sierre, S; Silva, M; Szhafir, I; Teplisky, D, 2021
)
0.62
"Technical success and primary occlusion were achieved in all patients with no adverse events."( Mechanochemical Endovenous Ablation of Varicose Veins in Pediatric Patients with Klippel-Trénaunay Syndrome: Feasibility, Safety, and Initial Results.
Cabezas, M; Garriga, M; Lambert, G; Oliva, A; Sierre, S; Silva, M; Szhafir, I; Teplisky, D, 2021
)
0.62
"MOCA is feasible and appears to be a safe and effective technique for treatment of varicose veins in pediatric patients with KTS."( Mechanochemical Endovenous Ablation of Varicose Veins in Pediatric Patients with Klippel-Trénaunay Syndrome: Feasibility, Safety, and Initial Results.
Cabezas, M; Garriga, M; Lambert, G; Oliva, A; Sierre, S; Silva, M; Szhafir, I; Teplisky, D, 2021
)
0.62
"To analyze adverse events (AEs) related to sclerosants reported through the Federal Adverse Event Reporting System (FAERS)."( Analysis of adverse events with sclerosants reported to the United States Food and Drug Administration.
Nguyen, CN; Nguyen, QD; Silapunt, S, 2022
)
0.72
" The minor adverse event rate for the cohorts was 14."( Safety of High-Dose 3% Sodium Tetradecyl Sulfate for Sclerotherapy of Renal Cysts in Patients with Autosomal Dominant Polycystic Kidney Disease.
Hsiao, R; Iliuta, IA; Jaberi, A; Kachura, JR; Nasser, M; Patel, NR; Pei, Y; Shlomovitz, E; Stella, SF; Tai, E, 2022
)
0.72
"To evaluate factors that contribute to adverse events (AEs) after embolization of venous malformations (VMs) using sclerosing agents."( Factors Affecting Adverse Events after Venous Malformation Sclerotherapy.
Kim, KR; Lee, SY, 2022
)
0.72
"We found that intervention with foam sclerotherapy using STS 3% is clinically effective and safe for patients with VMs and was most successful for those with Puig type I and II VMs."( Efficacy and safety of foam sclerotherapy with sodium tetradecyl sulfate as preferred sclerosant of venous malformations based on experience from a single specialist center.
Arasakumar, DRB; Brookes, J; Evans, N; Hamilton, G; Khalifa, M; Lim, CS; Pang, C; Papadopoulou, A; Tsui, J, 2023
)
0.91
"Foam sclerotherapy was clinically effective and safe for patients with AVM."( Efficacy and safety of embolo-sclerotherapy of arteriovenous malformations with foam sodium tetradecyl sulphate.
Arasakumar, DR; Brookes, J; Evans, N; Hamilton, G; Khalifa, M; Lim, CS; Pang, C; Papadopoulou, A; Tsui, J, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" More research is needed to determine the optimal agent(s) and the ideal dosing to achieve the best results and maximize patient satisfaction."( Sclerotherapy for lower limb telangiectasias.
Maxwell, H; Schwartz, L, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (18)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency89.35840.007215.758889.3584AID1224835
acetylcholinesteraseHomo sapiens (human)Potency89.35840.002541.796015,848.9004AID1347397
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency59.92063.189029.884159.4836AID1224846; AID1224894
AR proteinHomo sapiens (human)Potency4.60810.000221.22318,912.5098AID743042; AID743054
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency68.58960.000657.913322,387.1992AID1259378
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency6.16320.000214.376460.0339AID720691; AID720719
retinoid X nuclear receptor alphaHomo sapiens (human)Potency38.89520.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency68.58960.001530.607315,848.9004AID1224848; AID1224849; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency54.94100.375827.485161.6524AID743220
estrogen nuclear receptor alphaHomo sapiens (human)Potency61.64480.000229.305416,493.5996AID743075
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency55.30550.001024.504861.6448AID743212; AID743227
thyroid stimulating hormone receptorHomo sapiens (human)Potency61.13060.001628.015177.1139AID1259395
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency30.895619.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency48.96620.057821.109761.2679AID1159526
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency48.55770.000323.4451159.6830AID743065; AID743067
heat shock protein beta-1Homo sapiens (human)Potency61.64480.042027.378961.6448AID743210
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency68.58960.000627.21521,122.0200AID743202
Cellular tumor antigen p53Homo sapiens (human)Potency61.13060.002319.595674.0614AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (124)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Research

Studies (424)

TimeframeStudies, This Drug (%)All Drugs %
pre-199088 (20.75)18.7374
1990's73 (17.22)18.2507
2000's78 (18.40)29.6817
2010's151 (35.61)24.3611
2020's34 (8.02)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials49 (10.23%)5.53%
Reviews24 (5.01%)6.00%
Case Studies89 (18.58%)4.05%
Observational1 (0.21%)0.25%
Other316 (65.97%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (9)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Prospective Clinical Trial Evaluating the Efficacy of 1.5% Sodium Tetradecyl Sulfate Foam Injection for the Treatment of Epidermoid Cysts [NCT05597995]Phase 210 participants (Anticipated)Interventional2022-11-01Not yet recruiting
A Randomised Clinical Trial Comparing Endovenous Laser Ablation and Mechanochemical Ablation (ClariVein®) in the Management of Superficial Venous Insufficiency [NCT02627846]Phase 4150 participants (Actual)Interventional2015-06-01Completed
Balloon-occluded Retrograde Transvenous Obliteration Versus Endoscopic Tissue Glue Injection in the Prevention of Recurrent Gastric Variceal Bleeding [NCT06106971]Phase 368 participants (Anticipated)Interventional2018-06-28Recruiting
A Prospective, Randomized, Controlled, Multi-Center, Double Blind Study of ClariVein RES for Treatment of Venous Insufficiency Associated With Incompetent Saphenous Veins Due to Superficial Venous Reflux [NCT03311269]Phase 219 participants (Actual)Interventional2017-09-22Terminated(stopped due to Study was terminated for administrative reasons)
Pilot Randomised Controlled Trial Evaluating the Potential Benefit of a One Stop Vein Clinic (OSVeC) [NCT02557542]5 participants (Actual)Interventional2015-10-31Terminated(stopped due to Very poor recruitment)
A Randomised Clinical Trial Comparing Standard Cannula Delivered Foam Sclerotherapy, Catheter Directed Foam Sclerotherapy and ClariVein® Mechanochemical Ablation in the Management of Superficial Venous Insufficiency. [NCT02010437]Phase 40 participants (Actual)Interventional2014-01-31Withdrawn(stopped due to Study design has been substantially revised and a new registration will be made in the future.)
is Ultrasound-guided Foam Sclerotherapy a Cost-effective Alternate for Treatment of Varicose Veins? [NCT04655417]Early Phase 170 participants (Anticipated)Interventional2020-02-21Recruiting
Randomized Trial of Perforator Vein Injection for Symptomatic Venous Disease [NCT03363633]12 participants (Actual)Interventional2010-03-31Terminated(stopped due to difficulty recruiting)
Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia [NCT01408732]Phase 1/Phase 218 participants (Actual)Interventional2011-02-28Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01408732 (1) [back to overview]Severityof Epistaxis
NCT03311269 (2) [back to overview]Patient-Reported Symptoms 7-Day Symptom Questionnaire (Heaviness, Achiness, Swelling, Throbbing & Itching) to Evaluate Improvement in Subject Reported Symptoms.
NCT03311269 (2) [back to overview]Elimination of Saphenous Vein Reflux

Severityof Epistaxis

The primary outcome measure will be severity of epistaxis as measured by the Epistaxis Severity Score (ESS). The ESS, a recently developed online questionarrie that calculates the grading system for epistaxis severity. The higher the score the more severe the nose bleeds are Scale consists of several questions with a range of scale from 0-5 The average score is calculated for a final assessment (NCT01408732)
Timeframe: Change from Baseline to 14 weeks

Interventionunits on a scale (Mean)
Sclerotherapy Intervention-0.4578
Standard Treatment-1.4375

[back to top]

Patient-Reported Symptoms 7-Day Symptom Questionnaire (Heaviness, Achiness, Swelling, Throbbing & Itching) to Evaluate Improvement in Subject Reported Symptoms.

The VEINES-QOL (VEnous INsufficiency Epidemiological and Economic Study Quality of Life) comprises 25 items that quantify disease effect on quality-of-life, & a symptom questionnaire (VEINES-Sym) with 10 items that measure physical symptoms. A subset of the reported symptoms to Question 1 of the VEINES QOL/Sym is referred to as the 7-Day Symptom Questionnaire was used in this study. Subject response to each symptom was rated on a common 4-point response scale with lower scores representing better daily health outcomes (4=all day, 3=several times today, 2=once today, 1=not today). Weekly average score was calculated if at least 4 daily scores were present in the previous week. Daily total symptom score derived as sum of the responses across all symptoms (range = 5 to 20) Improvement in patient reported symptoms using the 7-Day Symptom Questionnaire (Heaviness, Achiness, Swelling, Throbbing & Itching) at post-treatment Week 12 compared to Baseline is the primary endpoint of this study. (NCT03311269)
Timeframe: 12 weeks

Interventionunits on a scale (Mean)
ClariVein RES 1% Injection7.2
ClariVein RES 3% Injection6.2

[back to top]

Elimination of Saphenous Vein Reflux

Evaluated by way of duplex ultrasound and read by Core Lab. Elimination of saphenous vein reflux can be achieved when ultrasound images demonstrate vein closure (no discrete open segment of vein > 5cm in length within the treatment section of the selected saphenous vein), or vein competency (defined as absence of retrograde flow > 0.5 seconds within any open portions of the treatment section of the selected saphenous vein) as assessed by duplex ultrasound. Responder = subjects who satisfies criteria for elimination of saphenous vein reflux (NCT03311269)
Timeframe: 12 weeks

,
InterventionParticipants (Count of Participants)
Vein Closure : YesVein Closure : NoVein Closure : MissingVein Competency : YesVein Competency : NoVein Competency : MissingVein Competency: No open segments > 5cmSaphenous Vein Reflux: Non-ResponderSaphenous Vein Reflux: Responder
ClariVein RES 1% Injection550230537
ClariVein RES 3% Injection900000909

[back to top]